Sanofi Nigeria Reinforces Commitment To Healthcare Management | Independent Newspapers Limited
Newsletter subscribe


 Sanofi Nigeria Reinforces Commitment To Healthcare Management

Posted: Jun 28, 2015 at 12:01 am   /   by   /   comments (0)

Phillip Oladunjoye , Lagos

Sanofi Nigeria has said that it has reinforces its sustained commitment to healthcare management through the provision of affordable medicines that are tailored to the needs of patients.

Sanofi.svgThe company noted that with the introduction of APROVASC®, a fixed-dose combination treatment for the management of hypertension, it now offers a wide range of treatment options for patients with hypertension.

Sanofi said that to better support the patients in the management of their disease, it had continued with its access to healthcare ambition in the opening of diabetes and hypertension clinics in partnership with health authorities, noting that the first clinic was inaugurated at the Lagos State University Teaching Hospital (LASUTH) on January 29, 2015.

The company lamented that in Nigeria, about 28.9% of the population had raised blood pressure while about 82% were not aware of this disease condition, noting that by 2030, up to 39.1 million people aged at least 20 years may live with hypertension1 if nothing is done to reverse the trend.

It said people with uncontrolled hypertension are exposed to many complications including stroke, heart attack, kidney failure and problems with vision, which can be controlled by adopting healthy diets, lifestyle changes and, in many cases, treatment with medications.

Sanofi said with over 90 years’ experience in development and manufacturing, it has become a world leader in delivering quality, innovative solutions to meet the needs of patients, noting that the APROVASC® range offers dosage flexibility that allows for individualized treatment.

General Manager, Sanofi Nigeria-Ghana, Abderrahmane Chakibi, said, “By introducing a new antihypertensive treatment, Sanofi demonstrates its commitment to patients through improving access to high quality solutions in the field of hypertension management in Nigeria. APROVASC® introduction is another example of Sanofi’s engagement to always provide advanced and innovative treatments in response to patients’ specific needs with the highest efficacy and comfort. This unique combination is the result of years of development, clinical studies and safety proofing.”

He added that: “Delivering innovative treatments and a full portfolio adapted to the needs of patients locally is at the core of what we, at Sanofi, have done for nearly a century. But medications alone are not enough. For many years, we have been supporting healthcare professionals in their daily practice through training and other tailored services. Through leveraging APROVASC® availability in Nigeria, Sanofi will continue to contribute to making the lives of Nigerian hypertensive patients healthier.”

He said that the introduction of new APROVASC® range, and the continual support of establishing clinics for the better management of the disease, was in direct response to the healthcare needs of patients with hypertension in Nigeria.